Ensign Group Stock: The Quiet Skilled-Nursing Compounder Beat AND Raised — Our BUY Call (ENSG)

The Ensign Group (ENSG) Q2 2026 — The Ensign Group (ENSG), a decentralized operator of skilled-nursing and post-acute facilities plus its captive real-estate arm Standard Bearer, reported Q2 2026 (quarter ended June 30, 2026): adjusted diluted EPS of $1.92 beat the ~$1.80 consensus and rose 20.8% YoY, with GAAP diluted EPS of $1.68 (+16.7%). Revenue grew 17.3% to $1.44B (from $1.23B). Same-facility occupancy climbed to 84.1% (+2.7 pts) and transitioning-facility occupancy to 84.7%, while skilled-mix days rose 6.2% (same-facility) and 9.4% (transitioning) and managed-care revenue jumped up to 16.2% — the occupancy-plus-mix combination that drives margins. Standard Bearer rental revenue grew 40.2% to $44.1M with FFO up 34.6% to $24.7M; Ensign now owns 183 real-estate assets and runs 398 operations across 17 states, having added 20 new operations (all with real estate) in the quarter and 102 since 2024. Management RAISED FY2026 guidance again — adjusted EPS to $7.75-$7.85 (from $7.48-$7.62) and revenue to $5.87-$5.92B — the midpoint +18.7% over 2025 and +41.8% over 2024. Liquidity is $262.3M cash + $591.6M revolver; net debt ~3x EBITDA; Q2 free cash flow $119M. The stock (~$173, +3.3% on the print) is ~21% off its $218 high after a 25% drawdown to $142. Our owner-earnings DCF (base +13% decel, 9% discount) lands fair value ~$205 — roughly 19% upside. Our call: BUY, 4/5. The Street also rates it Buy (~$218 avg target, 9 buys / 2 holds / 2 sells), so we're ALIGNED on the verdict, a touch more conservative on the target. The Ensign Group (ENSG) is one of the quietest compounders in healthcare — a decentralized operator of skilled-nursing and senior-living facilities that pushes decision-making down to local leaders, buys underperforming facilities cheap, fixes them, and compounds the cash (plus the real estate underneath, via its captive REIT-like arm Standard Bearer). Q2 2026 (ended June 30, 2026) was a beat AND a raise: adjusted diluted EPS of $1.92 topped the ~$1.80 estimate and rose 20.8% YoY, GAAP EPS was $1.68 (+16.7%), and revenue grew 17.3% to $1.44B. The engine is occupancy plus mix: same-facility occupancy rose to 84.1% (+2.7 pts), transitioning occupancy to 84.7%, skilled-mix days climbed 6.2%/9.4%, and managed-care revenue jumped as much as 16.2%. Standard Bearer's rental revenue grew 40.2% to $44.1M (FFO +34.6% to $24.7M); Ensign now owns 183 properties and runs 398 operations across 17 states, adding 20 new operations in Q2 (all with real estate) and 102 since 2024. Management RAISED FY2026 guidance for the second time this year — adjusted EPS to $7.75-$7.85 and revenue to $5.87-$5.92B, the midpoint +18.7% over 2025 and +41.8% over 2024. The balance sheet is solid: $262.3M cash + $591.6M revolver, net debt ~3x EBITDA, Q2 FCF $119M, a dividend raised 20+ years. The stock (~$173, +3.3% on the print) is ~21% below its $218 high after a 25% drawdown to $142 — while the fundamentals kept improving. We value ENSG as a compounder: owner earnings ~$465M (~$7.80/share) growing ~13% in our base case, run through an 8-9-10% DCF, lands fair value ~$205 — about 19% upside with a real margin of safety. Our call: BUY, 4/5 — a durable, self-funding compounder in an essential, aging-demographics business, still at a fair price. We're aligned with the Street's Buy (~$218 avg target, 9 buys / 2 holds / 2 sells), a shade more conservative on value. The honest caveats keep it from a 5: reimbursement risk (most revenue is Medicare/Medicaid), an aggressive acquisition pace, and ~3x leverage. Add on dips toward the mid-$150s; watch occupancy and skilled mix every quarter. Not financial advice. THE CALL: BUY (4/5, A DISCIPLINED, SELF-FUNDING COMPOUNDER STILL AT A FAIR PRICE — BEAT AND RAISED, WITH ~19% UPSIDE TO OUR FAIR VALUE) — base-case value ~$205 vs ~$173 today. What to watch: occupancy pushing past 85% with skilled mix still climbing, and the newly-acquired (transitioning) facilities ramping toward mature-facility margins the way prior cohorts have — that would extend the compounding and justify an upgrade toward the Street's $218; the risk to respect is the opposite — a material Medicaid or Medicare reimbursement cut, or signs the acquisition machine is overpaying and stumbling on integration at ~3x leverage, which would pressure both earnings and the multiple Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.